148 related articles for article (PubMed ID: 2464961)
21. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120.
Nara PL; Robey WG; Gonda MA; Carter SG; Fischinger PJ
Proc Natl Acad Sci U S A; 1987 Jun; 84(11):3797-801. PubMed ID: 3473484
[TBL] [Abstract][Full Text] [Related]
22. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
[TBL] [Abstract][Full Text] [Related]
24. The first successful AIDS vaccine: immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
Moor-Jankowski J
J Med Primatol; 1991; 20(1):47-8. PubMed ID: 2051469
[No Abstract] [Full Text] [Related]
25. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
26. AIDS 1989. Vaccines and immunology: overview.
Laurence J; Schild GC
AIDS; 1989; 3 Suppl 1():S97-100. PubMed ID: 2514762
[No Abstract] [Full Text] [Related]
27. [Immunization against the human immunodeficiency virus in Zaire].
Zagury D; Salaün JJ; Bernard J; Dechazal L; Goussard B; Lurhuma Z
Med Trop (Mars); 1988; 48(4):417-23. PubMed ID: 3221792
[TBL] [Abstract][Full Text] [Related]
28. Protection from secondary human immunodeficiency virus type 1 infection in chimpanzees suggests the importance of antigenic boosting and a possible role for cytotoxic T cells.
Balla-Jhagjhoorsingh SS; Mooij P; ten Haaft PJ; Bogers WM; Teeuwsen VJ; Koopman G; Heeney JL
J Infect Dis; 2001 Jul; 184(2):136-43. PubMed ID: 11424009
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxic T lymphocytes in HIV-induced disease: implications for therapy and vaccination.
Plata F; Dadaglio G; Chenciner N; Hoffenbach A; Wain-Hobson S; Michel F; Langlade-Demoyen P
Immunodefic Rev; 1989; 1(3):227-46. PubMed ID: 2698642
[TBL] [Abstract][Full Text] [Related]
30. The immune response to HIV: implications for vaccine development.
Bolognesi DP
Semin Immunol; 1993 Jun; 5(3):203-14. PubMed ID: 8347841
[TBL] [Abstract][Full Text] [Related]
31. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals.
Walker BD; Flexner C; Paradis TJ; Fuller TC; Hirsch MS; Schooley RT; Moss B
Science; 1988 Apr; 240(4848):64-6. PubMed ID: 2451288
[TBL] [Abstract][Full Text] [Related]
33. What are the correlates of protection?
Cohen J
Science; 1993 May; 260(5112):1259. PubMed ID: 8493565
[No Abstract] [Full Text] [Related]
34. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.
Fouts TR; Bagley K; Prado IJ; Bobb KL; Schwartz JA; Xu R; Zagursky RJ; Egan MA; Eldridge JH; LaBranche CC; Montefiori DC; Le Buanec H; Zagury D; Pal R; Pavlakis GN; Felber BK; Franchini G; Gordon S; Vaccari M; Lewis GK; DeVico AL; Gallo RC
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E992-9. PubMed ID: 25681373
[TBL] [Abstract][Full Text] [Related]
35. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
[TBL] [Abstract][Full Text] [Related]
36. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques.
Wagner R; Deml L; Notka F; Wolf H; Schirmbeck R; Reimann J; Teeuwsen V; Heeney J
Intervirology; 1996; 39(1-2):93-103. PubMed ID: 8957675
[TBL] [Abstract][Full Text] [Related]
38. Prospects for an AIDS vaccine.
Girard M
Cancer Detect Prev; 1990; 14(3):411-3. PubMed ID: 2117487
[TBL] [Abstract][Full Text] [Related]
39. Prospects for HIV vaccines.
Ada GL
J Acquir Immune Defic Syndr (1988); 1988; 1(3):295-303. PubMed ID: 3265153
[TBL] [Abstract][Full Text] [Related]
40. HIV-specific cytotoxic T lymphocytes in seropositive individuals.
Walker BD; Chakrabarti S; Moss B; Paradis TJ; Flynn T; Durno AG; Blumberg RS; Kaplan JC; Hirsch MS; Schooley RT
Nature; 1987 Jul 23-29; 328(6128):345-8. PubMed ID: 3496541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
